PLIVA Announces Approval for Citalopram Hydrobromide Tablets
PLIVA d.d. announced that PLIVA Inc., its US generics subsidiary, has received final approval from the U.S. food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Citalopram Hydrobromide Tablets 10 mg, 20 mg, and 40 mg. Citalopram Hydrobromide is the AB-rated generic equivalent of Forest Laboratories' Celexa, from a class of medications called selective serotonin reuptake inhibitors (SSRIs), used for the treatment of depression.
Most read news
Other news from the department research and development

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.